Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
After nearly 7 years of follow-up, the phase 3 PERSEUS trial confirms that adding daratumumab to the VRd regimen delivers a dramatic and durable survival edge in transplant-eligible multiple myeloma patients. The D-VRd-DR combo cut the risk of disease progression or death by 65% compared to standard VRd, with 72-month PFS rates of 81.1% vs. 56.1%. Impressively, most patients who stopped daratumumab per protocol stayed off the drug and remained in remission.
Long-term data from the phase 3 PERSEUS trial, presented at the 23rd International Myeloma Society Annual Meeting, confirm that daratumumab added to bortezomib, lenalidomide, and dexamethasone (D-VRd) followed by daratumumab-lenalidomide (DR) maintenance delivers deep, durable benefits in transplant-eligible newly diagnosed multiple myeloma. At a median follow-up of 81.3 months, the D-VRd-DR regimen cut the risk of progression or death by 65% compared to standard VRd with lenalidomide maintenance — and the median PFS was not even reached in the daratumumab arm.
The benefits extended across patient subgroups, including those with high-risk cytogenetics, and MRD negativity rates were roughly double with the daratumumab-based regimen. Notably, nearly three-quarters of patients on DR maintenance successfully stopped daratumumab per a protocol-guided MRD criteria — and most stayed off the drug without relapsing, a meaningful quality-of-life win.
By the Numbers
Why it matters: These results reinforce D-VRd as the standard of care for transplant-eligible newly diagnosed myeloma, while also validating MRD-guided treatment discontinuation as a viable strategy — potentially sparing patients from prolonged therapy without sacrificing outcomes.
